The problem
Sickle-cell disease and transfusion-dependent beta thalassemia are written into the patient’s genome: misshapen or missing hemoglobin means chronic pain crises, constant transfusions, and organ damage for life. The only cure was a matched donor stem-cell transplant most patients never get.
How it works
CRISPR Therapeutics, founded in 2013 by Emmanuelle Charpentier (later a Nobel laureate for CRISPR), Shaun Foy, and Rodger Novak and headquartered in Zug, Switzerland, edits the defect away. CASGEVY takes the patient’s own blood stem cells, edits them ex vivo with CRISPR/Cas9 so they produce protective fetal hemoglobin, and reinfuses them — one course, durable effect. The strategic research collaboration with Vertex, running since 2015, carried CASGEVY through approval as the world’s first CRISPR-based therapy. The pipeline now reaches beyond blood disease: in-vivo liver editing (CTX310), the zugo-cel CAR-T in autoimmune disease and lymphomas (with a Lilly clinical-supply collaboration), siRNA programs with Sirius Therapeutics, and diabetes cell therapy.
Pain points
Lifelong transfusion dependence and unpredictable pain crises; donor-transplant scarcity and risk; and for the field, the unsolved leap from ex-vivo cell manipulation to safe editing directly inside the patient.
Business model
Shared CASGEVY economics with Vertex, which runs global development, manufacturing, and commercialization, layered with partnered pipeline programs and wholly owned candidates aimed at repeat approvals.
Challenges
Each cure is a logistical operation — cell collection, editing, conditioning, reinfusion — that only specialized centers can deliver, so uptake speed is the commercial question; meanwhile investors value the company on whether in-vivo editing and oncology programs prove there is a second act.
Funding
- Raised: public company (Nasdaq: CRSP) — historical raise totals not itemized here (MISSING).
- Valuation: market pricing moves with CASGEVY uptake and pipeline readouts (MISSING).
Latest — July 2026
The FDA approved expanded use of CASGEVY for people ages 2 years and older with sickle-cell disease or transfusion-dependent beta thalassemia — the first genetic therapy cleared for children that young for both conditions — widening the eligible population for the CRISPR pioneer’s flagship cure.